nirmatrelvir/ritonavir vs vasopressin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of nirmatrelvir/ritonavir and vasopressin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Vasopressin receptor antagonists tolvaptan ↑ tolvaptan Co-administration contraindicated due to potential for dehydration, hypovolemia and hyperkalemia [see Contraindications (4) ] .
Paxlovid
Vasostrict
Paxlovid is a medicine used to treat mild to moderate COVID-19 in adults. It helps prevent severe illness, hospitalization, or death in people at high risk.
Vasopressin injection helps raise blood pressure in adults with shock. It is used when fluids and other medicines don't work well enough.
Paxlovid treats mild to moderate COVID-19 in adults. You must be at high risk of your illness becoming severe. This includes needing to go to the hospital or possibly dying from COVID-19. Paxlovid is not for preventing COVID-19 before or after exposure.
Vasopressin injection is used to increase blood pressure. It is for adults who have vasodilatory shock. This is when blood vessels relax too much, causing low blood pressure. It is used when fluids and other medicines called catecholamines are not enough to raise blood pressure.
Paxlovid contains two medicines, nirmatrelvir and ritonavir. Nirmatrelvir stops the virus from multiplying in your body. Ritonavir helps nirmatrelvir stay in your body longer so it can work better.
Vasopressin is a hormone that makes blood vessels get tighter. This helps to increase blood pressure. It can also affect how your kidneys handle water.
- • Change in taste
- • Diarrhea
- • Decreased heart output
- • Slow heart rate
- • Fast or irregular heart rate
- • Low sodium levels in the blood
- • Reduced blood flow to the heart
- COVID-19 22,774
- COVID-19 coming back 20,089
- Change in taste 7,316
- Diarrhea 4,003
- Feeling sick to your stomach 2,620
- Hypotension 486
- Cardiogenic Shock 389
- Sepsis 380
- Multiple Organ Dysfunction Syndrome 375
- Condition Aggravated 359
Paxlovid can interact with many other medicines, causing serious or life-threatening problems. Before taking Paxlovid, tell your doctor about all the medicines you take. Your doctor may need to adjust the dose of your other medicines or monitor you more closely.
Vasopressin can worsen heart function. It can also cause a type of diabetes where you pee a lot. Your doctor will check your electrolytes and urine after you stop taking it.
There is not enough information about nirmatrelvir's safety during pregnancy. Studies on ritonavir in pregnant women have not shown an increased risk of birth defects. Talk to your doctor about the risks and benefits of taking Paxlovid if you are pregnant or breastfeeding.
Vasopressin may cause the uterus to contract, which could be a problem during pregnancy. Tell your doctor if you are pregnant or plan to become pregnant. It is not known if vasopressin passes into breast milk.
How to Read This nirmatrelvir/ritonavir vs vasopressin Comparison
nirmatrelvir/ritonavir is classified in the Antiviral (Protease Inhibitor Combination) drug class, while vasopressin sits within the Vasopressin Receptor Agonist class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, nirmatrelvir/ritonavir has 56,802 submissions while vasopressin has 1,989. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to this combination causes tolvaptan levels to rise because the body cannot get rid of it fast enough. this can lead to severe fluid loss and high potassium levels.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for nirmatrelvir/ritonavir or vasopressin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.